Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
34.75 USD | -2.36% | -3.34% | +24.09% |
Business Summary
Number of employees: 378
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Targeted Therapies
100.0
%
| 35 | 100.0 % | 12 | 100.0 % | -67.27% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 35 | 100.0 % | 12 | 100.0 % | -67.27% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Jack Anders
DFI | Director of Finance/CFO | 47 | 18-07-31 |
Wally Reiher
CTO | Chief Tech/Sci/R&D Officer | - | 15-07-31 |
Wei Lin
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-03-31 |
Steve Kelsey
CTO | Chief Tech/Sci/R&D Officer | 63 | 17-02-28 |
Peg Horn
COO | Chief Operating Officer | 61 | - |
Linnet Zia
PRN | Corporate Officer/Principal | - | 19-02-28 |
Jeff Cislini
LAW | General Counsel | 49 | 19-12-31 |
Daniel Simon
PRN | Corporate Officer/Principal | - | 22-08-31 |
Luan M. Wilfong
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 62 | 14-09-30 |
Alexis Borisy
BRD | Director/Board Member | 52 | 14-10-31 |
Sandra Horning
BRD | Director/Board Member | 75 | Nov. 08 |
Barbara Weber
BRD | Director/Board Member | 67 | 18-03-31 |
Thilo Schroeder
BRD | Director/Board Member | 42 | 18-02-28 |
Lorence Kim
BRD | Director/Board Member | 49 | 22-07-11 |
Director/Board Member | 66 | 15-02-28 | |
Flavia Borellini
BRD | Director/Board Member | 65 | 21-06-21 |
Sushil Patel
BRD | Director/Board Member | 53 | 22-06-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 170,250,408 | 159,826,812 ( 93.88 %) | 5,560,000 ( 3.266 %) | 93.88 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.09% | 5.86B | |
+4.09% | 43.84B | |
+9.45% | 41.68B | |
+45.72% | 41.25B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+1.28% | 12.29B | |
+29.70% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- RVMD Stock
- Company Revolution Medicines, Inc.